SPDR S&P Biotech ETF


Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

Цена последней сделки 149.35
Код ценной бумаги XBI
Полное наименование SPDR S&P Biotech ETF
Объем 7262000000
Изм за день, % 0.01
Комиссия 0.35
Дата основания Feb 06. 2006
Ссылка ссылка
Тип актива Equity
Индекс S&P Biotechnology Select Industry Index
Регион North America
Средний P/E 8.48
Дивиденды 0.19
5 летняя доходность 163.94
3 летняя доходность 68.26
Годовая доходность 61.07
Бета 1.44

Топ эмитентов

Эмитент Доля, %
Kodiak Sciences Inc. 1.04
Editas Medicine, Inc. 1.07
TG Therapeutics, Inc. 1.07
Alexion 1.12
Agios Pharmaceuticals, Inc. 1.2
Sage Therapeutics, Inc. 1.14
Ionis Pharmaceuticals 1.17
Intellia Therapeutics, Inc. 1.18
Neurocrine Biosciences 1.05
Exelixis 1.05
Alnylam Pharmaceuticals, Inc. 1.04
Twist Bioscience Corporation 1.04
Fate Therapeutics 1.02

Описание SPDR S&P Biotech ETF

XBI is one of a handful of biotech ETFs available, offering exposure to a corner of the market that can perform well during periods of consolidation and is capable of big jumps in the event of major drug approvals. XBI focuses on a narrow sector of the health care sector, and as such is probably too precise for most investors seeking to construct a long-term portfolio. However, this ETF can be useful for those seeking to fine tune exposure or for those bullish on the sector over the long run. XBI focuses exclusively on American stocks, and primarily consists of mid cap and small cap securities. XBI's portfolio is somewhat limited, though the equal-weighted methodology of the underlying index ensures that assets are balanced across all components. That feature can be particularly important in the biotech space, where specific companies are capable of turning in big gains over short periods of time. PBE and IBB are other ETF options for biotech exposure; those considering this sector should take a close look at depth of exposure and weighing methodology, as these factors can have a major impact on the risk and return profiles achieved.